Trade Setup Buy Target $102.10 Sell Target $113.75 Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung […]
Read MorePlus, MGM Resorts’ chairman and CEO steps down as the casino operator withdraws its financial forecast for 2020, and Pepsi and Incyte report earnings.
Read MoreTrade Setup Buy Target $2.48 Sell Target $3.04 DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers […]
Read MoreTrade Setup Buy Target $2.05 Sell Target $2.28 Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases.
Read MoreAny pressure on these 3 managed care stocks is a buying opportunity according to one Cantor Fitzgerald analyst.
Read MoreTrade Setup Buy Target $10.16 Sell Target $11.04 Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib […]
Read MorePlus, the UN has called for an investigation into whether the Saudi Crown Prince was involved in hacking Amazon’s Bezos’ iPhone, Tesla got another upgrade, and Boeing said it doesn’t expect regulatory approval for its 737 Max until mid-year.
Read MoreTrade Setup Buy Target $3.52 Sell Target $3.80 Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its […]
Read MoreTrade Setup Buy Target $1.79 Sell Target $2.10 Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered […]
Read MoreGoldman Sachs says all three Strong Buy stocks could see double-digit upside next year.
Read More